Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492488 · ClinicalTrials.gov registry record · Phase 1
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
A Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer, sponsored by Shanghai Miracogen.
- Active
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 2
- Study locations
NCT04492488: Active Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer, sponsored by Shanghai Miracogen.
NCT04492488 is a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer that is active but no longer recruiting, run by Shanghai Miracogen. The registered enrollment target is 129 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04492488, a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer, is active but no longer recruiting, sponsored by Shanghai Miracogen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
Primary Outcome
The dose level in which (i) less than 2 out of 6 patients in a treatment cohort experiences dose-limiting toxicity (DLT); or (ii) \<33% of an evaluable patient treatment cohort experiences DLT.
Conditions Studied
Interventions
- DRUG MRG002
Study Locations (2)
California
- University of California Irvine Chao Family Comprehensive Cancer Center - Orange
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04492488 still lists
NCT04492488 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (35% lower).
The record links to 3 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MRG002 is the first listed.
NCT04492488 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT04492488 about?
NCT04492488 is a clinical study titled "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer". The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophag...
What is the current status of trial NCT04492488?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2021-05-24. Estimated completion is 2024-12-31.
What conditions does trial NCT04492488 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer.
What interventions are being tested in trial NCT04492488?
The interventions under investigation include: MRG002 (DRUG).
Who is sponsoring clinical trial NCT04492488?
This trial is sponsored by Shanghai Miracogen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04492488 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04492488's enrollment target sits among peer trials
129 66th of 144 higher than 78 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI